ALSO NOTED: Roche, Protein Design expand collaboration; Mesalamine studies hit endpoints; Wyeth wins fen-phen judgments; and mu

> Roche and Protein Design are expanding their collaboration on daclizumab, with Roche paying $10 million up front. Report

> Two Phase III clinical studies of an advanced formulation of high-strength mesalamine, SPD476, being developed by Shire met their primary endpoints. Release

> Wyeth has won a favorable judgment in three lawsuits regarding fen-phen. Report

> Chutes & Ladders: NeoPharm has chosen Guillermo A. Herrera, formerly with Abbott Laboratories, as its new CEO. Report

> Schering-Plough is seeking Japanese approval for Temodal as a therapy for malignant glioma. Release

> American Pharmaceutical Partners and American BioScience have published Phase I data for Abraxane as a therapy for patients with advanced cancer. Release

> Human Genome Sciences has released safety and tolerability results from a Phase II study of HGS-ETR1 (mapatumumab) in patients with advanced colorectal cancer. Release

And Finally... Canadian researchers say that ginseng can play a small but significant role in reducing the number and severity of colds suffered. Article